temafloxacin

Temafloxacin is a synthetic fluoroquinolone antibiotic that was developed for the treatment of various bacterial infections, including lower respiratory tract infections (such as community-acquired pneumonia and exacerbations of chronic bronchitis), genitourinary tract infections (including prostatitis, gonococcal and non-gonococcal urethritis, cervicitis), and skin and soft tissue infections. Its mechanism of action involves inhibition of bacterial DNA gyrase and topoisomerase IV—enzymes essential for DNA replication, transcription, repair, and recombination. In gram-negative bacteria, DNA gyrase is the primary target; in gram-positive organisms, topoisomerase IV is preferentially inhibited. This interference leads to strand breakage in bacterial chromosomes and ultimately inhibits cell division[1][2][3][4]. Temafloxacin was well absorbed orally with high bioavailability (>90%) and good tissue penetration but was withdrawn from the market shortly after its 1992 approval due to serious adverse reactions such as allergic responses and hemolytic anemia[1][3][5].

Brand names

Omniflox

Other names

temafloxacin hydrochloride